FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2 , dated February 10, 2026, further strengthening FibroBiologics’ intellectual property portfolio in regenerative ...

A 3D culture platform unlocks extracellular vesicle therapy for fibrotic skin repair

Hypertrophic scarring affects a large proportion of patients following burns, trauma, or surgery and arises from prolonged fibroblast hyperactivity and excessive extracellular matrix accumulation.
Nasdaq

FibroBiologics Presents Research on Human Dermal Fibroblast Spheroids for Psoriasis Therapy at SID Annual Meeting

FibroBiologics, Inc., a biotechnology company focused on developing therapies for chronic diseases using fibroblasts, announced that Dr. Chuo Fang presented research at the Society for Investigative ...
Seeking Alpha

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
Nasdaq

FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
Hosted on MSN

OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR

We believe it will take a positive biologic process created through fibroblast or a stem cell through immunotherapy or gene therapy. The three ways we think you'll be able to cure chronic diseases ...